

Giorgio Inghirami

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/270689/publications.pdf>

Version: 2024-02-01

169
papers

11,522
citations

36203

51
h-index

30848

102
g-index

177
all docs

177
docs citations

177
times ranked

18237
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. <i>Nature Communications</i> , 2017, 8, 15618.	5.8	1,194
2	The anaplastic lymphoma kinase in the pathogenesis of cancer. <i>Nature Reviews Cancer</i> , 2008, 8, 11-23.	12.8	792
3	Stromal contribution to the colorectal cancer transcriptome. <i>Nature Genetics</i> , 2015, 47, 312-319.	9.4	520
4	Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. <i>Nature Medicine</i> , 2005, 11, 623-629.	15.2	406
5	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. <i>Cancer Cell</i> , 2015, 27, 516-532.	7.7	378
6	The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development. <i>Journal of Experimental Medicine</i> , 2012, 209, 1537-1551.	4.2	363
7	Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. <i>Oncogene</i> , 2002, 21, 1038-1047.	2.6	354
8	A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2014, 123, 1293-1296.	0.6	345
9	Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. <i>Blood</i> , 2015, 125, 1061-1072.	0.6	281
10	Squalene accumulation in cholesterol auxotrophic lymphomas prevents oxidative cell death. <i>Nature</i> , 2019, 567, 118-122.	13.7	262
11	Patient derived organoids to model rare prostate cancer phenotypes. <i>Nature Communications</i> , 2018, 9, 2404.	5.8	246
12	The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. <i>Clinical Cancer Research</i> , 2015, 21, 1628-1638.	3.2	237
13	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016, 29, 574-586.	7.7	227
14	Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. <i>Nature Medicine</i> , 2020, 26, 1114-1124.	15.2	216
15	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. <i>Blood</i> , 2019, 133, 1664-1676.	0.6	184
16	Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , 2014, 15, 730-737.	5.1	164
17	Gene Expression Profiling Uncovers Molecular Classifiers for the Recognition of Anaplastic Large-Cell Lymphoma Within Peripheral T-Cell Neoplasms. <i>Journal of Clinical Oncology</i> , 2010, 28, 1583-1590.	0.8	152
18	Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 125, 111-123.	0.6	151

#	ARTICLE	IF	CITATIONS
19	The genetics of nodal marginal zone lymphoma. <i>Blood</i> , 2016, 128, 1362-1373.	0.6	147
20	Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3019-3025.	0.8	129
21	TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. <i>Cancer Discovery</i> , 2018, 8, 1632-1653.	7.7	120
22	Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. <i>Cancer Discovery</i> , 2021, 11, 1468-1489.	7.7	119
23	Three-dimensional chromatin landscapes in T cell acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2020, 52, 388-400.	9.4	118
24	Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 652-660.	1.2	115
25	PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. <i>Nature Medicine</i> , 2012, 18, 1699-1704.	15.2	113
26	The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. <i>Nature Medicine</i> , 2008, 14, 676-680.	15.2	112
27	New and Old Functions of STAT3: A Pivotal Target for Individualized Treatment of Cancer. <i>Cell Cycle</i> , 2005, 4, 1131-1133.	1.3	111
28	Epigenomic evolution in diffuse large B-cell lymphomas. <i>Nature Communications</i> , 2015, 6, 6921.	5.8	111
29	Molecular Checkpoint Decisions Made by Subverted Vascular Niche Transform Indolent Tumor Cells into Chemoresistant Cancer Stem Cells. <i>Cancer Cell</i> , 2017, 31, 110-126.	7.7	108
30	Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. <i>Cancer Discovery</i> , 2020, 10, 440-459.	7.7	103
31	Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. <i>Blood</i> , 2012, 120, 1274-1281.	0.6	101
32	Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 764-769.	3.3	100
33	PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. <i>Blood</i> , 2013, 122, 2683-2693.	0.6	98
34	The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling. <i>Nature Cell Biology</i> , 2015, 17, 81-94.	4.6	97
35	Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. <i>Blood</i> , 2016, 127, 221-232.	0.6	97
36	PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. <i>Cancer Research</i> , 2017, 77, e62-e66.	0.4	92

#	ARTICLE	IF	CITATIONS
37	STAT3: A multifaceted oncogene. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10151-10152.	3.3	89
38	The Tyrosine Phosphatase Shp2 Interacts with NPM-ALK and Regulates Anaplastic Lymphoma Cell Growth and Migration. Cancer Research, 2007, 67, 4278-4286.	0.4	86
39	NPM-ALK Oncogenic Tyrosine Kinase Controls T-Cell Identity by Transcriptional Regulation and Epigenetic Silencing in Lymphoma Cells. Cancer Research, 2009, 69, 8611-8619.	0.4	86
40	microRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma. Blood, 2013, 122, 2083-2092.	0.6	84
41	Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nature Communications, 2018, 9, 2024.	5.8	80
42	Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. Blood, 2016, 127, 858-868.	0.6	76
43	Integrin $\alpha 5 \beta 1$ acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells. Blood, 2015, 125, 841-851.	0.6	74
44	THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nature Communications, 2017, 8, 14290.	5.8	74
45	Peripheral T cell lymphomas: from the bench to the clinic. Nature Reviews Cancer, 2020, 20, 323-342.	12.8	74
46	Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. Nature Immunology, 2019, 20, 86-96.	7.0	71
47	CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. Science Translational Medicine, 2019, 11, .	5.8	67
48	CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers. Molecular Cancer Therapeutics, 2012, 11, 670-679.	1.9	66
49	Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. Cell Reports, 2020, 30, 755-770.e6.	2.9	65
50	A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood, 2021, 138, 2828-2837.	0.6	65
51	Pegasus: a comprehensive annotation and prediction tool for detection of driver gene fusions in cancer. BMC Systems Biology, 2014, 8, 97.	3.0	60
52	A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood, 2019, 133, 1201-1204.	0.6	58
53	Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. Life Science Alliance, 2021, 4, e202000955.	1.3	56
54	The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation. Cancer Research, 2008, 68, 8899-8907.	0.4	54

#	ARTICLE	IF	CITATIONS
55	Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project. <i>Blood</i> , 2021, 138, 213-220.	0.6	53
56	AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. <i>Nature Communications</i> , 2018, 9, 222.	5.8	51
57	Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. <i>Journal of Clinical Investigation</i> , 2018, 128, 4397-4412.	3.9	51
58	T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 4640-4647.	2.5	50
59	Genetic and phenotypic attributes of splenic marginal zone lymphoma. <i>Blood</i> , 2022, 139, 732-747.	0.6	49
60	Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. <i>Blood Advances</i> , 2016, 1, 47-61.	2.5	48
61	PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. <i>Blood</i> , 2018, 132, 2026-2039.	0.6	48
62	Rapid identification of <i>BCR<sc>/sc>/sc>ABL<sc>/sc>1</i>-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-PCR polymerase chain reaction: clinical, prognostic and therapeutic implications. <i>British Journal of Haematology</i>, 2018, 181, 642-652.</i>	1.2	46
63	Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 13, 334-346.	2.3	43
64	Efficacy of a Cancer Vaccine against <i>ALK</i>-Rearranged Lung Tumors. <i>Cancer Immunology Research</i>, 2015, 3, 1333-1343.</i>	1.6	42
65	OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations. <i>Oncotarget</i> , 2016, 7, 84675-84687.	0.8	42
66	Molecular features of primary mediastinal B-cell lymphoma: involvement of p16INK4A, p53 and c-myc. <i>British Journal of Haematology</i> , 1999, 107, 106-113.	1.2	40
67	Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. <i>Leukemia</i> , 2019, 33, 696-709.	3.3	40
68	Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target. <i>Haematologica</i> , 2021, 106, 1693-1704.	1.7	40
69	The Influence of Tissue Ischemia Time on RNA Integrity and Patient-Derived Xenografts (PDX) Engraftment Rate in a Non-Small Cell Lung Cancer (NSCLC) Biobank. <i>PLoS ONE</i> , 2016, 11, e0145100.	1.1	38
70	Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	38
71	Microscale Bioadhesive Hydrogel Arrays for Cell Engineering Applications. <i>Cellular and Molecular Bioengineering</i> , 2014, 7, 394-408.	1.0	37
72	Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 383-387.	0.6	37

#	ARTICLE	IF	CITATIONS
73	Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. <i>Modern Pathology</i> , 2020, 33, 179-187.	2.9	37
74	Pathogenesis of Peripheral T Cell Lymphoma. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2018, 13, 293-320.	9.6	36
75	Cell of Origin and Immunologic Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma. <i>American Journal of Pathology</i> , 2020, 190, 2-10.	1.9	36
76	Anaplastic large-cell lymphoma. <i>Seminars in Diagnostic Pathology</i> , 2011, 28, 190-201.	1.0	33
77	Specification of fetal liver endothelial progenitors to functional zoned adult sinusoids requires c-Maf induction. <i>Cell Stem Cell</i> , 2022, 29, 593-609.e7.	5.2	32
78	Peripheral T-cell and NK cell lymphoproliferative disorders: cell of origin, clinical and pathological implications. <i>Immunological Reviews</i> , 2015, 263, 124-159.	2.8	30
79	The Transcriptional Regulator Sin3A Contributes to the Oncogenic Potential of STAT3. <i>Cancer Research</i> , 2019, 79, 3076-3087.	0.4	30
80	N- and K-Ras Oncogenes in Plasma Cell Dyscrasias. <i>Leukemia and Lymphoma</i> , 1994, 15, 17-20.	0.6	28
81	IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas. <i>Cancers</i> , 2018, 10, 21.	1.7	28
82	The heterogeneous landscape of ALK negative ALCL. <i>Oncotarget</i> , 2017, 8, 18525-18536.	0.8	28
83	Assessment of T-cell receptor repertoire and clonal expansion in peripheral T-cell lymphoma using RNA-seq data. <i>Scientific Reports</i> , 2017, 7, 11301.	1.6	27
84	Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL. <i>Journal of Hematology and Oncology</i> , 2018, 11, 105.	6.9	26
85	Etiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Current Directions in Research. <i>Cancers</i> , 2020, 12, 3861.	1.7	26
86	Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 2838-2840.	0.6	24
87	Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. <i>Leukemia and Lymphoma</i> , 2019, 60, 1626-1631.	0.6	23
88	Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL. <i>Blood</i> , 2021, 137, 788-800.	0.6	22
89	Repurposing dasatinib for diffuse large B cell lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 16981-16986.	3.3	21
90	Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. <i>Oncotarget</i> , 2016, 7, 79637-79653.	0.8	21

#	ARTICLE	IF	CITATIONS
91	Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 4019-4019.	0.6	20
92	Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 51, 680-688.	0.6	19
93	FYN-TRAF3IP2 induces NF- κ B signaling-driven peripheral T-cell lymphoma. <i>Nature Cancer</i> , 2021, 2, 98-113.	5.7	19
94	Mutation analysis links angioimmunoblastic T-cell lymphoma to clonal hematopoiesis and smoking. <i>ELife</i> , 2021, 10, .	2.8	19
95	Anaplastic lymphoma kinase inhibitors. <i>Current Opinion in Pharmacology</i> , 2015, 23, 39-44.	1.7	17
96	Phospholipid scramblase 1 as a critical node at the crossroad between autophagy and apoptosis in mantle cell lymphoma. <i>Oncotarget</i> , 0, 7, 41913-41928.	0.8	17
97	Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice. <i>Journal of Clinical Oncology</i> , 2022, 40, 4261-4275.	0.8	17
98	Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 628-634.	2.0	16
99	Myeloproliferative and lymphoproliferative malignancies occurring in the same patient: a nationwide discovery cohort. <i>Haematologica</i> , 2020, 105, 2432-2439.	1.7	16
100	Cytokine-Induced Killer Cells Engineered with Exogenous T-Cell Receptors Directed Against Melanoma Antigens: Enhanced Efficacy of Effector Cells Endowed with a Double Mechanism of Tumor Recognition. <i>Human Gene Therapy</i> , 2015, 26, 220-231.	1.4	15
101	Durable Responses Observed with JAK Inhibition in T-Cell Lymphomas. <i>Blood</i> , 2018, 132, 2922-2922.	0.6	15
102	Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas. <i>Cancer Research</i> , 2021, 81, 5202-5216.	0.4	14
103	Pulmonary adenocarcinoma with enteric differentiation: Dissecting oncogenic genes alterations with DNA sequencing and FISH analysis. <i>Experimental and Molecular Pathology</i> , 2017, 102, 276-279.	0.9	13
104	Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma. <i>Human Pathology</i> , 2018, 75, 167-178.	1.1	13
105	The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK ⁺ anaplastic large cell lymphoma by regulating the DNA helicase HELLS. <i>Leukemia</i> , 2020, 34, 2964-2980.	3.3	13
106	Metabolic and Immune Markers for Precise Monitoring of COVID-19 Severity and Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 809937.	2.2	13
107	PKC β /1 inhibition activates an ULK2-mediated interferon response to repress tumorigenesis. <i>Molecular Cell</i> , 2021, 81, 4509-4526.e10.	4.5	12
108	Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. <i>Onc Immunology</i> , 2018, 7, e1341032.	2.1	11

#	ARTICLE	IF	CITATIONS
109	A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries. <i>Cancers</i> , 2020, 12, 1603.	1.7	11
110	Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities. <i>Oncotarget</i> , 2016, 7, 25064-25086.	0.8	11
111	Transcriptional Analysis of Lennert Lymphoma Reveals a Unique Profile and Identifies Novel Therapeutic Targets. <i>Frontiers in Genetics</i> , 2019, 10, 780.	1.1	10
112	Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML. <i>Frontiers in Oncology</i> , 2021, 11, 701318.	1.3	10
113	The DNA-helicase HELLS drives ALK ⁺ ALCL proliferation by the transcriptional control of a cytokinesis-related program. <i>Cell Death and Disease</i> , 2021, 12, 130.	2.7	10
114	Refractory T-Cell Prolymphocytic Leukemia with JAK3 Mutation: In Vitro and Clinical Synergy of Tofacitinib and Ruxolitinib. <i>Blood</i> , 2015, 126, 5486-5486.	0.6	10
115	Multiparametric in situ imaging of NPM1-mutated acute myeloid leukemia reveals prognostically-relevant features of the marrow microenvironment. <i>Modern Pathology</i> , 2020, 33, 1380-1388.	2.9	9
116	A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma. <i>Blood</i> , 2016, 128, 150-150.	0.6	9
117	Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma. <i>Scientific Reports</i> , 2020, 10, 13094.	1.6	8
118	The Coding Genome of Nodal Marginal Zone Lymphoma Reveals Recurrent Molecular Alterations of PTPRD and Other Jak/Stat Signaling Genes. <i>Blood</i> , 2014, 124, 705-705.	0.6	8
119	A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies. <i>Blood</i> , 2014, 124, 4417-4417.	0.6	7
120	Three-dimensional growth of breast cancer cells potentiates the anti-tumor effects of unacylated ghrelin and AZP-531. <i>ELife</i> , 2020, 9, .	2.8	7
121	The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States. <i>Blood</i> , 2018, 132, 1702-1702.	0.6	6
122	Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling. <i>Blood</i> , 2019, 134, 656-656.	0.6	6
123	High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study. <i>Blood</i> , 2021, 138, 138-138.	0.6	5
124	Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL ² Phase 1a study. <i>British Journal of Haematology</i> , 2018, 182, 453-456.	1.2	4
125	Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusion-associated myeloid neoplasm. <i>Blood Advances</i> , 2022, 6, 1137-1142.	2.5	4
126	The Brd-Inhibitor OTX015 Shows Pre-Clinical Activity in Anaplastic Large T-Cell Lymphoma (ALCL). <i>Blood</i> , 2012, 120, 4872-4872.	0.6	4

#	ARTICLE	IF	CITATIONS
127	Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B cell lymphoma. <i>Haematologica</i> , 2021, , .	1.7	3
128	The Brd-Inhibitor OTX015 Is Active in Pre-Clinical Models of Mature B-Cell Lymphoid Tumors. <i>Blood</i> , 2012, 120, 1657-1657.	0.6	3
129	Genetic Mechanisms of Immune Escape in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2014, 124, 1692-1692.	0.6	3
130	Extracellular Nicotinamide Phosphoribosyltransferase (NAMPT) Shapes the CLL Microenvironment Promoting Macrophage M2 Polarization Via a Non-Enzymatic Mechanism. <i>Blood</i> , 2014, 124, 3316-3316.	0.6	3
131	Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia. <i>British Journal of Haematology</i> , 2000, 111, 263-271.	1.2	2
132	Kinomic profiling of tumour xenografts derived from patients with non-“small cell lung cancer confirms their fidelity and reveals potentially actionable pathways. <i>European Journal of Cancer</i> , 2021, 144, 17-30.	1.3	2
133	Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. <i>Blood</i> , 2018, 132, 922-922.	0.6	2
134	Anaplastic Lymphoma Kinase activating mechanisms and signaling pathways. <i>Frontiers in Bioscience - Scholar</i> , 2015, 7, 283-305.	0.8	2
135	Transposable elements: The enemies within. <i>Experimental Hematology</i> , 2016, 44, 913-916.	0.2	1
136	Are we ready to take full advantage of patient-“derived tumor xenograft models?. <i>Hematological Oncology</i> , 2018, 36, 24-27.	0.8	1
137	In Vivo and Ex Vivo Patient-“Derived Tumor Xenograft Models of Lymphoma for Drug Discovery. <i>Current Protocols</i> , 2021, 1, e96.	1.3	1
138	High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Profiling: A Combined Analysis from Two Phase 2 Trials. <i>Blood</i> , 2018, 132, 2962-2962.	0.6	1
139	Shared Genomic Alterations in Patients with Co-Existing Myeloproliferative Neoplasms and Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 2776-2776.	0.6	1
140	Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways. <i>Blood</i> , 2016, 128, 4096-4096.	0.6	1
141	Novel Long Non Coding RNA Blackmamba Is Associated to ALK- anaplastic Large Cell Lymphoma. <i>Blood</i> , 2016, 128, 461-461.	0.6	1
142	JAK-STAT in lymphoproliferative disorders. <i>Oncoscience</i> , 2015, 2, 737-738.	0.9	1
143	VAV1 Activating Mutations and Translocations in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2016, 128, 2741-2741.	0.6	1
144	Cell cycle inhibitiON to target the EVolution of urOthelial cancer (CLONEVO): A single-arm, open-label window-of-opportunity trial of neoadjuvant abemaciclib in platinum-ineligible muscle invasive bladder cancer patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS606-TPS606.	0.8	1

#	ARTICLE	IF	CITATIONS
145	Diffuse Large B Cell Pdx in Humanized Mice Are Valuable Models to Study Host-Lymphoma Interactions and Immune-Modulating Agents. <i>Blood</i> , 2021, 138, 2406-2406.	0.6	1
146	The Genomic Landscape of Plasmablastic Lymphoma (PBL) - an L.L.M.P.P. Project. <i>Blood</i> , 2021, 138, 1326-1326.	0.6	1
147	Cytoskeleton Dynamics in Peripheral T Cell Lymphomas: An Intricate Network Sustaining Lymphomagenesis. <i>Frontiers in Oncology</i> , 2021, 11, 643620.	1.3	0
148	Constant Activation of the RAF-MEK-ERK Pathway As a Diagnostic and Therapeutic Target in Hairy Cell Leukemia.. <i>Blood</i> , 2012, 120, 2657-2657.	0.6	0
149	The PD-1/PD-L1 Axis Contributes to T Cell Dysfunction in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 1778-1778.	0.6	0
150	Genetic Factors Predicting The Response To BET Bromodomain Inhibitors In Lymphoma Lead To New Synergistic Combinations. <i>Blood</i> , 2013, 122, 3070-3070.	0.6	0
151	Integrin $\alpha 2 \beta 3$ Transduces Survival and Angiogenic Signals to T Cell Lymphomas and Is a Therapeutic Target. <i>Blood</i> , 2014, 124, 510-510.	0.6	0
152	Identification of a New Subclass of ALK Negative Anaplastic Large Cell Lymphoma Expressing Aberrant Levels of ERBB4 Transcripts. <i>Blood</i> , 2014, 124, 1679-1679.	0.6	0
153	Convergent Mutations and New Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2014, 124, 781-781.	0.6	0
154	Assessment of T-Cell Receptor Repertoire and Clonal Expansion in Peripheral T-Cell Lymphoma Using RNA-Seq Data. <i>Blood</i> , 2015, 126, 1451-1451.	0.6	0
155	The Pro-Tumorigenic Vascular Niche Sustains the T-Cell Acute Lymphoblastic Leukemia Phenotype and Fosters Resistance to Therapy. <i>Blood</i> , 2016, 128, 279-279.	0.6	0
156	HSP90 Facilitates Oncogene-Induced Metabolic Reprogramming in B-Cell Lymphomas. <i>Blood</i> , 2017, 130, 645-645.	0.6	0
157	Hematopoietic Stem Cell Transplant in Novel Agent Era Is Associated with Improved Survival in Relapsed and Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2018, 132, 1640-1640.	0.6	0
158	A Clinical Review of the Co-Occurrence of Myeloproliferative and Lymphoproliferative Neoplasms. <i>Blood</i> , 2018, 132, 4285-4285.	0.6	0
159	Heat Shock Factor 1 Reprograms the DLBCL Microenvironment to Evade Immune Surveillance and Support Tumor Growth. <i>Blood</i> , 2018, 132, 2854-2854.	0.6	0
160	Mapping MALT1 Signaling Connectivity Unveils Novel B-Cell Feedback Mechanisms Directing Assembly of Potent Anti-Lymphoma Regimens. <i>Blood</i> , 2019, 134, 173-173.	0.6	0
161	Heterogeneous Genetic Alterations and Novel Pathogenic Pathways in Relapsed DLBCL Revealed By Whole Exome Sequencing. <i>Blood</i> , 2019, 134, 2770-2770.	0.6	0
162	The DNA Helicase Hells Is a New Unconventional Player in ALK- Anaplastic Large Cell Lymphoma Biology. <i>Blood</i> , 2019, 134, 1477-1477.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Dynamic Immune Surveillance in Durable Clinical Response to Combined BTK and BCL2 Inhibition in MCL at Longitudinal Single-Cell Resolution. Blood, 2021, 138, 1323-1323.	0.6	0
164	Selective STAT3 Degradation Dissects Peripheral T-Cell Lymphoma Vulnerabilities Empowering Personalized Regimens. Blood, 2021, 138, 865-865.	0.6	0
165	HHV-6 in the Lymphoma Microenvironment: Both Chicken and Egg?. Blood, 2021, 138, 1377-1377.	0.6	0
166	FOXO1 Dependent Transcription Network Is a Targetable Vulnerability of Mantle Cell Lymphoma. Blood, 2021, 138, 30-30.	0.6	0
167	A Predictive Endothelial-Leukemia Pre-Clinical Platform to Uncover Drug Vulnerabilities for Personalized Treatments. Blood, 2021, 138, 704-704.	0.6	0
168	519. Immune responses and COVID-19 severity. Open Forum Infectious Diseases, 2020, 7, S325-S325.	0.4	0
169	XPO1 Relieves MYC-Induced Replication Stress Limiting the Immunogenicity of DLBCL Cells. Blood, 2020, 136, 18-18.	0.6	0